文献速递前列腺癌

他汀类药物与前列腺癌:炒作还是希望?生物学视角

Statins and prostate cancer-hype or hope? The biological perspective.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-06-29

本文综述他汀类药物在前列腺癌中抗肿瘤作用的生物学证据,描述失调的甲羟戊酸代谢途径在前列腺癌进展中的功能作用,并总结靶向该通路(含他汀类及其他药物)治疗前列腺癌的生物学依据与原理。

要点

  • 他汀类是HMGCR(甲羟戊酸通路限速酶)的强效特异性抑制剂。
  • 观察性证据提示使用他汀与晚期前列腺癌风险降低及治疗结局改善相关。
  • 他汀抗肿瘤机制尚未充分阐明,可能涉及多重机制。

核心结论

  • 越来越多证据提示因控制胆固醇而接受他汀处方的男性晚期前列腺癌风险更低且治疗结局更好,但他汀发挥抗肿瘤作用的机制尚不明确且可能为多重机制。

研究设计与样本

  • 本文为两部分系列综述之一,回顾他汀作为前列腺癌抗癌药物的观察性与实验性数据。

主要发现

  • 本文描述失调的甲羟戊酸代谢在前列腺癌进展中的功能作用。

关键数值与推荐

  • 他汀类是3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)的强效特异性抑制剂,HMGCR是甲羟戊酸(MVA)代谢通路的限速酶。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Growing evidence suggests that men prescribed a statin for cholesterol control have a lower risk of advanced prostate cancer (PCa) and improved treatment outcomes; however, the mechanism by which statins elicit their anti-neoplastic effects is not well understood and is likely multifaceted. Statins are potent and specific inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway. This two-part series is a review of the observational and experimental data on statins as anti-cancer agents in PCa. In this article, we describe the functional role that deregulated MVA metabolism plays in PCa progression and summarize the biological evidence and rationale for targeting the MVA pathway, with statins and other agents, for the treatment of PCa.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Longo J, Freedland SJ, Penn LZ, et al. Statins and prostate cancer-hype or hope? The biological perspective. Prostate Cancer Prostatic Dis. 2022. PMID: 35768578. doi:10.1038/s41391-022-00557-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。